April 28 (Reuters) - XOMA Corp XOMA.O :

* Finalizes plans for gevokizumab phase 3 clinical program in pyoderma

gangrenosum

* Says based on meeting with FDA, the company is finalizing its plans for a

gevokizumab phase 3 program in pyoderma gangrenosum

* Source text for Eikon ID:nGNXVAJZIa

* Further company coverage XOMA.O

((Bangalore Newsroom; +1 646 223 8780))